ARMP — Armata Pharmaceuticals, Inc.

NYSE · Health Care · Biotechnology · CIK 921114 ·
Last close
$5.17
Market Cap
$192.23M
52W High
$8.92
52W Low
$3.48
ADV30
141,471
Next earnings
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -8,785,000 -115,346,000 69,800,000 4,754,000 381,386,000
Dec 2025 0 -8,411,000 -124,298,000 76,882,000 8,688,000 295,478,000
Sep 2025 0 -7,776,000 -26,675,000 89,516,000 14,756,000 185,104,000
Jun 2025 0 -6,844,000 -16,295,000 80,790,000 4,328,000 150,293,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-23,965,000
Investing CF
$-506,000
Financing CF
$16,267,000
CapEx
$-506,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-4.55
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-616,880,000
Inventory
Receivables
$47,000
ST Investments
EBIT TTM
$-264,067,000
Pretax Income TTM
$-282,614,000
Interest Exp TTM
$18,547,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,543,000
EBITDA
$-33,448,000
Free Cash Flow
$-27,409,624
Enterprise Value
$482,231,840
Total Cash
$23,952,000
Total Debt
$313,952,992
Shares Out
37,181,979
Trailing EPS
$-5.29
Book Value
$-6.22
ROE
ROA
-25.8%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -31,222,000 -173,799,000 76,882,000 295,478,000 -25,763,000
Dec 2024 0 -42,436,000 -18,916,000 86,437,000 134,456,000 -37,551,000
Dec 2023 0 -40,890,000 -69,045,000 98,363,000 130,428,000 -47,423,000
Dec 2022 0 -36,946,000 -36,917,000 95,834,000 59,754,000 -32,481,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.57

Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $5.58 · call volume: 2 · put volume: 1
Expected Move to 2026-09-18: ±$1.38 (24.64%) — implied range $4.20$6.95 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PLX Protalix BioTherapeutics, Inc. $194.18M $2.41
IPHYF Innate Pharma SA $184.31M $1.65
HUMA Humacyte, Inc. $183.96M $0.66
CHRS Coherus Oncology, Inc. $210.12M $1.36
CRBU Caribou Biosciences, Inc. $175.82M $1.64

News headlines (Yahoo Finance, 1h cache)

Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
2026-07-21 11:05 · Yahoo
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
2026-07-20 11:00 · Yahoo
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
2026-07-13 11:00 · Yahoo
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
2026-06-23 11:00 · Yahoo
Here’s Why Armata Pharmaceuticals Inc. (ARMP) is a High Growth Micro-Cap Stock to Buy?
2026-06-19 18:18 · Yahoo
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
2026-05-13 20:30 · Yahoo
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
2026-05-07 11:00 · Yahoo
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
2026-05-04 11:00 · Yahoo
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
2026-08-12 20:05 · Yahoo
Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength
2026-05-08 21:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.